🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

CORRECTED - WHO sending Tamiflu stocks to 72 countries for flu

Published 05/05/2009, 11:03 AM
GSK
-

(corrects final para to say Relenza known generically as zanamivir, not oseltamivir)

* WHO to send 2.4 million Tamiflu courses to 72 countries

* Swiss drugmaker Roche donated rapid response stockpile

GENEVA, May 5 (Reuters) - The World Health Organisation said on Tuesday it would begin sending 2.4 million treatment courses of Tamiflu, an antiviral proven effective against the new flu, to 72 countries deemed in need, including Mexico.

The Swiss drugmaker Roche Holding AG donated the stockpiles to the United Nations agency several years ago for use in a possible influenza pandemic.

"The WHO is dispatching 2.4 million courses of antivirals to 72 countries most in need, including Mexico," WHO spokeswoman Fadela Chaib told a news briefing in Geneva.

"Part of the stock will be dispatched today (Tuesday)."

Shipments will be made from "three hubs" -- Switzerland, Maryland, in the United States, and Dubai in the United Arab Emirates, she said.

The WHO will also supplement its regional stockpiles in its six regions for "contingency" use in countries which may suffer outbreaks of the new H1N1 virus, according to Chaib.

Roche said on Saturday the WHO had asked it to deploy its so-called rapid response stockpiles and that it was also increasing production to meet rising demand.

GlaxoSmithKline, the world's second largest drugmaker, said last Friday it was increasing production of Relenza, a flu drug which must be inhaled.

Tamiflu and Relenza, known generically as oseltamivir and zanamivir respectively, are the only two approved drugs to which the new strain of influenza A H1N1 has been found to be susceptible. (Reporting by Stephanie Nebehay; Editing by Michael Kahn and Jon Hemming)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.